Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.
Profitability
This table compares Alaunos Therapeutics and AbbVie’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Alaunos Therapeutics | N/A | -267.77% | -209.18% |
AbbVie | 7.59% | 257.91% | 12.44% |
Institutional & Insider Ownership
27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 5.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 0.3% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Alaunos Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
AbbVie | 0 | 5 | 17 | 2 | 2.88 |
AbbVie has a consensus target price of $208.35, suggesting a potential upside of 8.24%. Given AbbVie’s stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Alaunos Therapeutics.
Volatility & Risk
Alaunos Therapeutics has a beta of -0.4, indicating that its share price is 140% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Earnings and Valuation
This table compares Alaunos Therapeutics and AbbVie”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Alaunos Therapeutics | N/A | N/A | -$35.14 million | N/A | N/A |
AbbVie | $56.33 billion | 6.04 | $4.28 billion | $2.40 | 80.20 |
AbbVie has higher revenue and earnings than Alaunos Therapeutics.
Summary
AbbVie beats Alaunos Therapeutics on 11 of the 12 factors compared between the two stocks.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
About AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.